Annexon Inc (ANNX)

$3.93 -0.20 (-4.95%)
Market Cap 828.46M
Revenue (ttm) 0.00
Net Income (ttm) -206.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,931,858
Avg Vol 3,194,818
Day's Range N/A - N/A
Shares Out 189.58M
Stochastic %K 3%
Beta 1.21
Analysts Strong Sell
Price Target $15.50

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
Biotech80
Biotech80 Sep. 11 at 8:47 PM
$ANNX Wait until week 48 then enter - patience is the key here
1 · Reply
Lightening_strikes
Lightening_strikes Sep. 11 at 7:49 PM
$ANNX management has a serious credibility issue
0 · Reply
NewBee13
NewBee13 Sep. 11 at 7:37 PM
$ANNX Quit acting like a turd and go up
1 · Reply
Rickylinderman
Rickylinderman Sep. 11 at 5:35 PM
$ANNX Shana Tovah from Rosenthal and thanks for your donations. Whew
0 · Reply
raj3406
raj3406 Sep. 11 at 2:46 PM
$ANNX Buy zone
1 · Reply
dcrown
dcrown Sep. 11 at 2:22 PM
$ANNX
0 · Reply
Sly15
Sly15 Sep. 11 at 2:07 PM
$ANNX Anytime this wants to quit acting like a Stonk would be alright. Looking forward to December
0 · Reply
Lightening_strikes
Lightening_strikes Sep. 11 at 1:49 PM
$ANNX something is off here
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Sep. 11 at 10:58 AM
$ANNX There are two, not one like most irons in the fire. GBS and GA. I personally bought more at $4.10. GBS will be approved and the floor will be $6-7 EMA, $10-15 with an FDA approval. Buy when there is blood in the streets.
2 · Reply
dcrown
dcrown Sep. 10 at 7:10 PM
$ANNX bottom $1.05 be ready
1 · Reply
Latest News on ANNX
Annexon Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2026, 1:35 PM EDT - 1 day ago

Annexon Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Annexon Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 9, 2026, 8:45 AM EDT - 2 days ago

Annexon Transcript: Wells Fargo 21st Annual Healthcare Conference

Annexon to Participate in Upcoming September Investor Conferences

Sep 2, 2026, 8:00 AM EDT - 9 days ago

Annexon to Participate in Upcoming September Investor Conferences

Annexon price target raised to $14 from $10 at JPMorgan

2026-09-01T12:10:49.000Z - 10 days ago

Annexon price target raised to $14 from $10 at JPMorgan

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Aug 17, 2026, 4:05 PM EDT - 25 days ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon participates in a conference call with JPMorgan

2026-08-17T15:56:01.000Z - 25 days ago

Annexon participates in a conference call with JPMorgan

Annexon reports Q2 EPS (28c), consensus (24c)

2026-08-17T10:15:55.000Z - 25 days ago

Annexon reports Q2 EPS (28c), consensus (24c)

Annexon expands Phase 3 ARCHER II trial

2026-08-17T10:15:38.000Z - 25 days ago

Annexon expands Phase 3 ARCHER II trial

Annexon upgraded to Market Perform from Underperform at Citizens

2026-08-17T08:34:37.000Z - 25 days ago

Annexon upgraded to Market Perform from Underperform at Citizens

Annexon Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Annexon Earnings Call Transcript: Q2 2026

Annexon Earnings release: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Annexon Earnings release: Q2 2026

Annexon Quarterly report: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Annexon Quarterly report: Q2 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Aug 12, 2026, 6:05 AM EDT - 4 weeks ago

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Aug 12, 2026, 6:00 AM EDT - 4 weeks ago

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Annexon announces tanruprubart data from FORWARD study

2026-08-06T14:00:43.000Z - 5 weeks ago

Annexon announces tanruprubart data from FORWARD study

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

Jul 30, 2026, 4:01 PM EDT - 6 weeks ago

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

Annexon initiated with an Underperform at Citizens

2026-07-21T08:45:13.000Z - 7 weeks ago

Annexon initiated with an Underperform at Citizens

Annexon price target raised to $25 from $11 at Needham

2026-07-15T11:55:10.000Z - 1 month ago

Annexon price target raised to $25 from $11 at Needham

Annexon to present vonaprument data at ASRS

2026-07-14T20:15:31.000Z - 1 month ago

Annexon to present vonaprument data at ASRS

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Jul 14, 2026, 4:05 PM EDT - 1 month ago

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Nedham biotech analysts hold an analyst/industry conference call

2026-07-02T17:40:09.000Z - 2 months ago

Nedham biotech analysts hold an analyst/industry conference call

Annexon Transcript: AGM 2026

Jun 11, 2026, 11:00 AM EDT - 3 months ago

Annexon Transcript: AGM 2026

Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 8:00 AM EDT - 3 months ago

Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Annexon Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 3 months ago

Annexon Transcript: Jefferies Global Healthcare Conference 2026

Annexon to Participate in Upcoming June Investor Conferences

May 27, 2026, 8:00 AM EDT - 3 months ago

Annexon to Participate in Upcoming June Investor Conferences

Annexon Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 4 months ago

Annexon Transcript: Bank of America Global Healthcare Conference 2026

Annexon initiated with a Neutral at Goldman Sachs

2026-05-12T09:15:39.000Z - 4 months ago

Annexon initiated with a Neutral at Goldman Sachs

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

May 11, 2026, 10:00 AM EDT - 4 months ago

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

Annexon reports Q1 EPS (23c), consensus (30c)

2026-05-07T21:46:09.000Z - 4 months ago

Annexon reports Q1 EPS (23c), consensus (30c)

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 7, 2026, 4:01 PM EDT - 4 months ago

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Annexon Quarterly report: Q1 2026

Annexon Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Annexon Earnings release: Q1 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

Annexon to Present at the Bank of America Securities Health Care Conference 2026

Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Annexon Proxy statement: Proxy filing

Annexon Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Annexon Proxy statement: Proxy filing

Annexon Slides: Corporate presentation

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Annexon Slides: Corporate presentation

Annexon Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Annexon Proxy statement: Proxy filing

Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 11:45 AM EDT - 4 months ago

Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 5 months ago

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal

2026-03-31T17:10:51.000Z - 5 months ago

Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal

APLS BIIB OCGN

Annexon files automatic mixed securities shelf

2026-03-31T10:20:07.000Z - 5 months ago

Annexon files automatic mixed securities shelf

Annexon reports Q4 EPS (28c), consensus (32c)

2026-03-30T20:18:52.000Z - 5 months ago

Annexon reports Q4 EPS (28c), consensus (32c)

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 30, 2026, 4:01 PM EDT - 5 months ago

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Annexon Earnings release: Q4 2025

Annexon Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Annexon Annual report: Q4 2025

Annexon Transcript: KOL event

Mar 18, 2026, 2:00 PM EDT - 5 months ago

Annexon Transcript: KOL event

Annexon Slides: KOL event

Mar 18, 2026, 2:00 PM EDT - 5 months ago

Annexon Slides: KOL event

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Mar 16, 2026, 4:05 PM EDT - 5 months ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 6 months ago

Annexon Transcript: TD Cowen 46th Annual Health Care Conference

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 6 months ago

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Feb 17, 2026, 8:00 AM EST - 6 months ago

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Annexon Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 8 months ago

Annexon Transcript: 44th Annual J.P. Morgan Healthcare Conference

Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 8 months ago

Annexon Slides: 44th Annual J.P. Morgan Healthcare Conference

Annexon highlights its 2026 strategic priorities

2026-01-12T12:39:27.000Z - 8 months ago

Annexon highlights its 2026 strategic priorities

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Jan 12, 2026, 7:00 AM EST - 8 months ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon submits MAA to EMA for tanruprubart

2026-01-08T13:05:13.000Z - 8 months ago

Annexon submits MAA to EMA for tanruprubart

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Jan 8, 2026, 8:00 AM EST - 8 months ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 8 months ago

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon initiated with a Buy at Chardan

2025-12-23T09:35:20.000Z - 8 months ago

Annexon initiated with a Buy at Chardan

Annexon initiated with a Buy at Clear Street

2025-12-01T21:20:32.000Z - 9 months ago

Annexon initiated with a Buy at Clear Street

Annexon price target raised to $27 from $14 at Wells Fargo

2025-11-19T11:35:39.000Z - 9 months ago

Annexon price target raised to $27 from $14 at Wells Fargo

Annexon Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:30 AM EST - 9 months ago

Annexon Transcript: Jefferies London Healthcare Conference 2025

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 14, 2025, 4:01 PM EST - 10 months ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 10:55 PM EST - 10 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 10 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Nov 10, 2025, 4:05 PM EST - 10 months ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Annexon Earnings release: Q3 2025

Annexon Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Annexon Quarterly report: Q3 2025

Annexon Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Annexon Transcript: Cantor Global Healthcare Conference 2025

Annexon Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:00 PM EDT - 1 year ago

Annexon Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Annexon Earnings release: Q2 2025

Annexon Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Annexon Quarterly report: Q2 2025

Annexon Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Annexon Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Annexon Slides: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Annexon Slides: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Annexon Transcript: Jefferies Global Healthcare Conference 2025

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 1 year ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 1 year ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Earnings release: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Earnings release: Q1 2025

Annexon Quarterly report: Q1 2025

May 12, 2025, 12:30 PM EDT - 1 year ago

Annexon Quarterly report: Q1 2025

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 1 year ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 1 year ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing

Annexon Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Annexon Proxy statement: Proxy Filing

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 1 year ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 11:50 AM EST - 1 year ago

Annexon Transcript: TD Cowen 45th Annual Healthcare Conference

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Annual report: Q4 2024

Mar 3, 2025, 12:00 AM EST - 1 year ago

Annexon Annual report: Q4 2024

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 1 year ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Annexon Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Annexon Slides: FY 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Annexon Slides: FY 2025

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Transcript: Study Result

Annexon Press release: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Press release: Study Result

Annexon Slides: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

Annexon Slides: Study Result

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 5:30 AM EST - 1 year ago

Annexon Transcript: Jefferies London Healthcare Conference 2024

Annexon Quarterly report: Q3 2024

Nov 14, 2024, 9:30 AM EST - 1 year ago

Annexon Quarterly report: Q3 2024

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Annexon Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:05 PM EDT - 1 year ago

Annexon Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Annexon Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 9:30 AM EDT - 2 years ago

Annexon Transcript: 2024 Wells Fargo Healthcare Conference

Annexon Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Annexon Quarterly report: Q2 2024

Annexon Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Annexon Earnings release: Q2 2024

Annexon Registration statement: Registration Filing

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Annexon Registration statement: Registration Filing

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 2 years ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 2 years ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 2 years ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 2 years ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon Transcript: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Transcript: Study Update

Annexon Press release: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Press release: Study Update

Annexon Slides: Study Update

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Annexon Slides: Study Update

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 2 years ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 2 years ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Biotech80
Biotech80 Sep. 11 at 8:47 PM
$ANNX Wait until week 48 then enter - patience is the key here
1 · Reply
Lightening_strikes
Lightening_strikes Sep. 11 at 7:49 PM
$ANNX management has a serious credibility issue
0 · Reply
NewBee13
NewBee13 Sep. 11 at 7:37 PM
$ANNX Quit acting like a turd and go up
1 · Reply
Rickylinderman
Rickylinderman Sep. 11 at 5:35 PM
$ANNX Shana Tovah from Rosenthal and thanks for your donations. Whew
0 · Reply
raj3406
raj3406 Sep. 11 at 2:46 PM
$ANNX Buy zone
1 · Reply
dcrown
dcrown Sep. 11 at 2:22 PM
$ANNX
0 · Reply
Sly15
Sly15 Sep. 11 at 2:07 PM
$ANNX Anytime this wants to quit acting like a Stonk would be alright. Looking forward to December
0 · Reply
Lightening_strikes
Lightening_strikes Sep. 11 at 1:49 PM
$ANNX something is off here
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Sep. 11 at 10:58 AM
$ANNX There are two, not one like most irons in the fire. GBS and GA. I personally bought more at $4.10. GBS will be approved and the floor will be $6-7 EMA, $10-15 with an FDA approval. Buy when there is blood in the streets.
2 · Reply
dcrown
dcrown Sep. 10 at 7:10 PM
$ANNX bottom $1.05 be ready
1 · Reply
Thomas105
Thomas105 Sep. 10 at 6:50 PM
$ANNX anyone see a bottom? 4.01?
2 · Reply
Lightening_strikes
Lightening_strikes Sep. 10 at 5:52 PM
$ANNX wow
1 · Reply
Rickylinderman
Rickylinderman Sep. 10 at 5:47 PM
$ANNX red for months. Whew
1 · Reply
Lightening_strikes
Lightening_strikes Sep. 10 at 4:42 PM
$ANNX two blockbuster drugs Lolz
0 · Reply
Lightening_strikes
Lightening_strikes Sep. 10 at 4:31 PM
$ANNX preserves vision?
1 · Reply
elmono
elmono Sep. 10 at 1:20 PM
$ANNX some insider buying might help…or funds 😂😂😂
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 10 at 12:25 PM
$ANNX Time for Love to give himself some more options…
2 · Reply
Lightening_strikes
Lightening_strikes Sep. 9 at 8:50 PM
$ANNX bloodbath
0 · Reply
Montu11
Montu11 Sep. 9 at 6:57 PM
$ANNX target was reevaluated to $14 from $10 by JP Morgan… then decides to free-fall… can we get an analyst to say reevaluate to $1 a share so it can skyrocket? None of this makes sense.
3 · Reply
Lightening_strikes
Lightening_strikes Sep. 9 at 4:11 PM
$ANNX today it’s rates Tomorrow?
0 · Reply
Sly15
Sly15 Sep. 9 at 2:37 PM
$ANNX good update this morning. Interesting points, 1) greater than 50% of patients in phase 3 vonoprument already at month 15 and events are tracking as expected. 2) Market size, only 20% of patients are currently being treated for GA with syforvey and Izervey in the us. Current gross sales for both are 1.0 Billion and don't help vision. Likely Vonoprument a replacement plus gaining patients. Europe is at least as large as a market as US if not Larger. 10:36 AM
1 · Reply
Lightening_strikes
Lightening_strikes Sep. 9 at 2:21 PM
$ANNX stock doesn’t care about updates Wants something done
0 · Reply